Chuangyebang was informed that on April 25, Beijing Lingfu Biotechnology Co., Ltd. (hereinafter referred to as: Lingfu Bio) completed a pre-A round of financing of over 200 million yuan, led by China Life Equity and jointly led by Legend Capital. Chang Development Capital, Puhua Capital, Saifu Medicine and other institutions followed the investment, and Probe Capital served as the financial advisor.
This round of financing is mainly used for the layout of experimental animal resource bases and laboratories.
Lingfu Bio was co-incubated and established by well-known companies such as Beijing Saifu Pharmaceutical Research Institute Co., Ltd. (hereinafter referred to as “Saifu Medicine”), Beijing Renyuan Xinsheng Biotechnology Co., Ltd. and a team of laboratory animal industry experts. Prior to this, Lingfu Bio has completed nearly 50 million yuan in angel round financing.
Lingfu Bio is committed to becoming the first scientific research service provider in China that integrates the entire industrial chain of experimental animals, the entire industrial chain of animal models and high value-added scientific research services, enabling life science innovation.
At present, Lingfu Bio has deployed the Yangtze River Delta experimental beagle and marmoset resource base, Hainan experimental cynomolgus monkey and miniature pig animal resource base, forming the main experimental animal breeding, conservation breeding, import substitution, and building high The ability of the quality industry chain provides resources for the R&D, innovation and experimentation of biopharmaceutical industry enterprises, top scientific research institutions, hospitals and other customers.
The company mainly selects brain science, nervous system, and tumor as the key directions to create innovative model products; it has a large number of innovative technologies and practical capabilities in the evaluation of animal behavior, brain stereotaxy, molecular imaging technology, etc., to help life The innovation of medical science is advancing to a deeper level, a wider field, and a higher level, providing strong technical support for the high-quality development of the scientific research industry. Lingfu Bio has a number of animal houses and laboratories in Beijing and Shenzhen, with a total area of nearly 20,000 square meters in operation and under construction, serving animal scientific research services in the biomedical industry in the Beijing-Tianjin-Hebei and Guangdong-Hong Kong-Macao Greater Bay Area.
Regarding the investment in Lingfu Bio, the lead investor China Life Equity said: “Experimental animals and model animals are important tools to support life science innovation, with great potential for industry upgrading and a broad domestic alternative space. Lingfu Bio has a leading ability to guarantee animal resources. It has the potential to become an industry leader with the ability to serve large animal models and is expected to become the first research service provider in my country that integrates the entire industrial chain of experimental animals, the entire industrial chain of animal models, and high-value-added innovative scientific research services. China Life Equity hopes to join hands And help Lingfu Bio, build high-quality laboratory animal resource guarantee, build model animal world-class technical capabilities, bridge the gap from original innovation in life sciences to cutting-edge biomedicine industries, and enhance the autonomy and stability of my country’s life science industry chain, Help the high-quality development of the industry.”
Wang Jianfei, Managing Director of Legend Capital, said: “The laboratory animal industry helps improve efficiency and reduce costs in the R&D stage of drugs and medical devices; the demand for laboratory animals and model animals continues to grow rapidly every year, while the distribution of animal resources in China is fragmented and large animal models are prepared. The ability is scarce; the Lingfu biological team has rich experience in company operation and management, and has accumulated many years in experimental animal breeding and animal model preparation. We are honored to cooperate with Lingfu biological and look forward to its rapid realization of the full industrial chain coverage of experimental animals and becoming a domestic The most complete category of high-quality laboratory animal resource providers and featured animal model providers.”
Ms. Zhang Lei, Chairman of Lingfu Biology, said: “The original intention of Lingfu Biology is to build China’s experimental animal resource industry chain and at the same time polish model animals with high added value, especially those that are difficult, scarce and significant. In our opinion, good experimental animals and model animals are inseparable from good scientific innovation, and the two complement each other, support and promote each other. We are very grateful to the investors for their high recognition. The Pre-A round of financing has been over-raised by a large proportion, and the entire team of Lingfu Bio will surely move forward and live up to high expectations. At the same time, it is particularly important to introduce that Lingfu Bio has created an open public resource platform, and industries are welcome More partners in the country to work together.”
attached
For more project information, please go to “Rui Beast Analysis” .
media coverage
The investment community invests in China Net Venture State
Related events
- Laboratory animal research service provider Lingfu Bio has completed a pre-A round of financing of over 200 million yuan2022-04-25
- Zhenzhun Bio received an exclusive Series A investment of over 100 million yuan from Huiyuan Capital2022-03-09
- Stem cell therapy cutting-edge “Xueji Bio” completed 100 million yuan Pre-A round of financing2022-02-25
- Baiyin Bio completed the angel round of financing, Wuyuan’s exclusive investment2021-12-16
- Comma Bio completed the Series A financing of over 100 million yuan2021-11-10
This article is reproduced from: https://readhub.cn/topic/8fuJ7TuDu3E
This site is for inclusion only, and the copyright belongs to the original author.